Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD - Nature Biotechnology

  • 📰 NatureBiotech
  • ⏱ Reading Time:
  • 7 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 6%
  • Publisher: 63%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD

This work was funded by the Commonwealth Fund, as well as from a grant to W.B.F. A.S.K.’s work was also supported by Arnold Ventures. R.B.’s work is funded by an O’Brien Institute of Public Health catalyst grant for equitable pharmaceutical innovation and access to medicines. The funders had no role in the design and conduct of the study; collection, management, analysis or interpretation of the data; review or approval of the manuscript; or decision to submit the manuscript for publication.

Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.

Brand name inhalers are very good at blocking competition, better even than nebulizers, study finds NBTintheNews via endpts

BrighamWomens harvardmed UCalgaryMed PORTAL_Research wbfeldman ReedBeall

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 231. in BR

Brasil Últimas Notícias, Brasil Manchetes